Perspectives
Traditional Drug Pipeline Monthly Update: November 2022
Critical updates in an ever changing environment
November 18, 2022This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.
See separate articles for pipeline information on specialty drugs.
New Drug Information
- Rezvoglar® (insulin glargine-aglr): The U.S. Food and Drug Administration (FDA) approved the second interchangeable biosimilar insulin product to Lantus® (insulin glargine), Eli Lilly’s Rezvoglar® (insulin glargine-aglr).1Rezvoglar is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. FDA previously approved Rezvoglar as a biosimilar to Lantus on December 17, 2021.
Generic Drug Information
- Daliresp® (roflumilast tablet): Multiple manufacturers have launched their generic version of AstraZeneca’s Daliresp for the treatment of chronic obstructive pulmonary disease (COPD). Daliresp generated $260 million in U.S. annual sales in 2021.
+Specialty medication
References
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761215
Related news
Perspectives
April 25, 2024
Clinical News: April 2024
Your monthly source for drug information highlights
Perspectives
April 25, 2024
Drug Approvals Monthly Update: April 2024
This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals…
Perspectives
April 25, 2024
Drug Approvals Quarterly Update: April 2024
This wrap-up provides a review of newly approved drugs, recent drug launches, new…